Exoxemis Exoxemis - Indications
Home Technology Indications Collaborations Company Publications Contact
Nosocosmial Infections Surgical Site Infection Biodefence
 
>

Nosocomial Infections

Multiple MPO formulations are in development for prevention of serious, and often resistant, hospital-acquired infections.
more >>

 
       
>

Surgical Site Infection Prevention

Our unique MPO formulation holds the promise of a breakthrough in surgical site infection prevention.
more >>

   
       
>

Biodefense

The MPO technology platform suggests the potential for use in preventing infections in conventional and biological attack situations.
more >>

   
       
>
E-mail Inquiries    
The myeloperoxidase (MPO) system is a versatile technology that lends itself to a variety of high value medical, biodefense, industrial, agricultural, and disinfection applications. Our primary R&D focus is on the prevention and treatment of serious and resistant infections.

Prevention of surgical site infection (SSI) is the lead indication for our proprietary technology. Surgical site infection is a common nosocomial infection associated with high morbidity, mortality, and hospital costs.

There is significant opportunity to leverage the unique properties of the myeloperoxidase (MPO) and eosinophil peroxidase (EPO) technology platform into multiple indications, including biodefense.